Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BC 3402

Next Previous
Drug Profile

BC 3402

Alternative Names: BC-3402

Latest Information Update: 19 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocity Biopharmaceutics
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Liver cancer
  • Phase I Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 07 Dec 2024 Adverse events and efficacy data from a phase I trial in Myelodysplastic syndromes and Chronic myelomonocytic leukaemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 25 Sep 2024 Case Comprehensive Cancer Center plans phase I/II trial in Liver cancer (Combination therapy, Late-stage disease and Unresectable) in US (IV) (NCT06608940)
  • 05 Apr 2024 Efficacy, adverse events, pharmacokinetics and pharmacodynamcis data from a phase I trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top